Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 KATP channels

Endocannabinoid Inhibition of Ion Channels of Pancreatic Beta Cells

(2011) Charles Spivak et al.   BIOPHYSICAL JOURNAL

Central Endocannabinoid Signaling Regulates Hepatic Glucose Production and Systemic Lipolysis

(2011) J. D. O'Hare et al.   DIABETES

Banting Lecture 2011: Hyperinsulinemia: Cause or Consequence?

(2011) B. E. Corkey   DIABETES

Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans

(2011) C. Li et al.   DIABETES OBESITY & METABOLISM

The role of the endocannabinoid system in islet biology

(2011) Máire E Doyle   Current Opinion in Endocrinology Diabetes and Obesity

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

(2010) Joseph Tam et al.   JOURNAL OF CLINICAL INVESTIGATION

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

(2010) Eric J Topol et al.   LANCET

Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding

(2009) Angelo A Izzo et al.   BRITISH JOURNAL OF PHARMACOLOGY

Six Months of Diazoxide Treatment at Bedtime in Newly Diagnosed Subjects With Type 1 Diabetes Does Not Influence Parameters of  -Cell Function and Autoimmunity but Improves Glycemic Control

(2009) M. A. Radtke et al.   DIABETES CARE

Beneficial effects of K-ATP channel openers in diabetes: an update on mechanisms and clinical experiences

(2009) V. Grill et al.   DIABETES OBESITY & METABOLISM

Beneficial effect of a chronic treatment with rimonabant on pancreatic function and β-cell morphology in Zucker Fatty rats

(2009) Valérie F. Duvivier et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sulfonylurea receptors and mechanism of sulfonylurea action

(2009) U. Panten et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

CB1 antagonists for obesity—what lessons have we learned from rimonabant?

(2009) Vincenzo Di Marzo et al.   Nature Reviews Endocrinology

The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets

(2009) Lisa Getty-Kaushik et al.   Obesity

Peripheral, but Not Central, CB1 Antagonism Provides Food Intake-Independent Metabolic Benefits in Diet-Induced Obese Rats

(2008) R. Nogueiras et al.   DIABETES

Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program

(2008) L. Van Gaal et al.   DIABETES CARE

Diazoxide prevents abdominal adiposity and fatty liver in obese OLETF rats at prediabetic stage

(2008) Zhiyong Guo et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Endocannabinoids: Some Like it Fat (and Sweet Too)

(2008) I. Matias et al.   JOURNAL OF NEUROENDOCRINOLOGY

Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats

(2008) Ramin Alemzadeh et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Impact of metabolic abnormalities for beta cell function: Clinical significance and underlying mechanisms

(2008) V GRILL et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

End of the line for cannabinoid receptor 1 as an anti-obesity target?

(2008) Dan Jones   NATURE REVIEWS DRUG DISCOVERY

Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet

(2008) Katarzyna M. Starowicz et al.   Obesity

KATP channel openers of the benzopyran type reach their binding site via the cytosol

(2006) D Stephan et al.   BRITISH JOURNAL OF PHARMACOLOGY